Multi-drug-resistant tuberculosis surgery

Multi-drug-resistant tuberculosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Multi-drug-resistant tuberculosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Multi-drug-resistant tuberculosis surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Multi-drug-resistant tuberculosis surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Multi-drug-resistant tuberculosis surgery
CDC on Multi-drug-resistant tuberculosis surgery
Multi-drug-resistant tuberculosis surgery in the news
Blogs on Multi-drug-resistant tuberculosis surgery
Directions to Hospitals Treating Multi-drug-resistant tuberculosis
Risk calculators and risk factors for Multi-drug-resistant tuberculosis surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Surgery

In extremely resistant disease, surgery is sometimes the last port of call. The centre with the largest experience in this is the National Jewish Medical and Research Center in Denver, Colorado. In 17 years of experience, they have performed 180 operations; of these, 98 were lobectomies, 82 were pneumonectomies. There is a 3.3% operative mortality, with an additional 6.8% dying following the operation; 12% experienced significant morbidity (particularly extreme breathlessness). Of 91 patients who were culture positive before surgery, only 4 were culture positive after surgery.